Abstract

具有表皮生长因子受体(epidermal growth factor receptor, EGFR)敏感突变的非小细胞肺癌患者对酪氨酸激酶抑制剂(tyrosine kinase inhibitors, TKIs)具有良好反应,但是即使存在相同突变,不同患者对TKIs的反应也不一致。推测突变分子含量的不同是TKIs反应不一的部分原因,具有更高EGFR突变“丰度”的肿瘤患者可能从TKIs中获益更多。EGFR突变可根据检测方法敏感性的不同,定量检测突变分子比例以及突变蛋白表达等进行半定量或定量检测。EGFR突变丰度可能有助于反映肿瘤异质性,评估疾病进程,预测TKIs药物敏感性,早期发现耐药,具有重要的临床意义。

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.